Contact Congress about H.R. 1082: Shandra Eisenga Human Cell and Tissue Product Safety Act

Companies and clinics that break certain FDA safety rules for human cell and tissue products could face new fines. The FDA would also publish more oversight data and run education efforts for health care workers and the public.

Modern Action explains legislation in plain English, helps you choose whether to support, oppose, or ask for changes, and drafts a message tied to the bill, your stance, and the elected officials who can act on it.

Shandra Eisenga Human Cell and Tissue Product Safety Act is a Senate bill in committee. The latest recorded action: Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Latest action on H.R. 1082: Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Who this affects: This bill mainly affects companies, clinics, tissue establishments, researchers, health care workers, patients, and the FDA. Companies and clinics would face new fines if they break certain safety rules. Health care workers would get more donation education. Patients and researchers could see clearer public information about how these products are overseen.

Why this matters: Patients can be harmed if human cell and tissue products are handled, tested, or used poorly. This bill tries to lower that risk by adding fines and making FDA oversight more public. It also asks whether current rules fit newer science, including stem cell and other cell-based therapies.

Key provisions in H.R. 1082

• The Secretary of Health and Human Services must help create and share donation education for health care workers. The materials cover organ, tissue, and eye donation, donor screening tests, and related issues.
• The bill adds new civil fines for breaking certain FDA rules for human cell and tissue products. These are products regulated under the Public Health Service Act rules for communicable-disease safety.
• A violation could cost up to $20,000. If it continues after written notice, the fine could add up to $20,000 per day, plus the retail value of the products involved, with a $10 million cap for one case.
• The FDA must post clear materials about its Tissue Reference Group. That group helps decide how human cell and tissue products fit under FDA rules.
• The FDA must publish yearly oversight data for three years, starting within one year after the bill becomes law. The data must include registered tissue establishments since 2019, inspections, how those compare with blood-bank inspections, Tissue Reference Group questions, and average response times.

How Modern Action helps you take action on H.R. 1082

You do not have to start with a blank letter. Modern Action turns the bill, your position, and the relevant congressional context into a message you can edit and send. The goal is to make contacting Congress clear, specific, and useful without forcing you to parse bill text or figure out the right office on your own.

Questions people ask about H.R. 1082

What is H.R. 1082?

Companies and clinics that break certain FDA safety rules for human cell and tissue products could face new fines. The FDA would also publish more oversight data and run education efforts for health care workers and the public.

How do I support or oppose H.R. 1082?

Choose support, oppose, or ask for changes on Modern Action. The action flow drafts the message for you and keeps the wording tied to this bill.

Who should I contact about H.R. 1082?

Modern Action uses your location to route the action to the congressional offices relevant to the bill and your representation.

Can Modern Action explain H.R. 1082 before I act?

Yes. Modern Action gives you a plain-English summary, current status, and action context before you send anything.